Literature DB >> 26866973

Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats.

Clayton T Bauer1, S Stevens Negus, Bruce E Blough, Matthew L Banks.   

Abstract

Phendimetrazine is a clinically available anorectic and candidate medication for the treatment of cocaine addiction. Phendimetrazine can be metabolized to the amphetamine-like monoamine releaser phenmetrazine, but it is unclear if phendimetrazine functions as an inactive prodrug or might have activity on its own. As one method to address this issue, the present study compared the potency and time course of phendimetrazine and phenmetrazine to produce cocaine-like discriminative stimulus effects in adult, male rats (N=5) trained to discriminate cocaine (5.6 mg/kg, intraperitoneally) from saline in a two-key food-reinforced discrimination procedure. We hypothesized that, if metabolism to phenmetrazine was required for phendimetrazine effects, then phendimetrazine would be less potent and have a slower onset and offset of effects than phenmetrazine. Both phendimetrazine and phenmetrazine produced dose-dependent cocaine-like discriminative stimulus effects, and phendimetrazine was 7.8-fold less potent than phenmetrazine. However, the time courses of discriminative stimulus effects produced by phendimetrazine and phenmetrazine were similar, with peak effects at 10 min and offset by 100 min. These results show the effectiveness of phendimetrazine to rapidly produce cocaine-like behavioral effects in rats and support other nonhuman primate evidence to suggest that metabolism to phenmetrazine may not be required for phendimetrazine effects.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26866973      PMCID: PMC4779707          DOI: 10.1097/FBP.0000000000000225

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  10 in total

1.  Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.

Authors:  Matthew L Banks; Clayton T Bauer; Bruce E Blough; Richard B Rothman; John S Partilla; Michael H Baumann; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2014-05-05       Impact factor: 3.157

2.  Effects of dopamine D1-like and D2-like agonists in rats trained to discriminate cocaine from saline: influence of experimental history.

Authors:  S B Caine; S S Negus; N K Mello; J Bergman
Journal:  Exp Clin Psychopharmacol       Date:  2000-08       Impact factor: 3.157

3.  A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil.

Authors:  David J Heal; Niki W Buckley; Jane Gosden; Nigel Slater; Charles P France; David Hackett
Journal:  Neuropharmacology       Date:  2013-06-06       Impact factor: 5.250

4.  Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain.

Authors:  Richard B Rothman; Marina Katsnelson; Nga Vu; John S Partilla; Christina M Dersch; Bruce E Blough; Michael H Baumann
Journal:  Eur J Pharmacol       Date:  2002-06-28       Impact factor: 4.432

5.  Role of phenmetrazine as an active metabolite of phendimetrazine: evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; Timothy R Fennell; Rodney W Snyder; S Stevens Negus
Journal:  Drug Alcohol Depend       Date:  2012-12-01       Impact factor: 4.492

6.  Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine.

Authors:  D M Wood; M W Emmett-Oglesby
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Amphetamine-like effects of anorectics and related compounds in pigeons.

Authors:  S M Evans; C E Johanson
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

8.  Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys.

Authors:  R de la Garza; C E Johanson
Journal:  J Pharmacol Exp Ther       Date:  1987-12       Impact factor: 4.030

9.  Effects of 14-day treatment with the schedule III anorectic phendimetrazine on choice between cocaine and food in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; S Stevens Negus
Journal:  Drug Alcohol Depend       Date:  2013-05-31       Impact factor: 4.492

10.  Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure.

Authors:  Matthew L Banks; Blake A Hutsell; Bruce E Blough; Justin L Poklis; S Stevens Negus
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-24       Impact factor: 5.176

  10 in total
  3 in total

1.  Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers.

Authors:  Gavin McLaughlin; Michael H Baumann; Pierce V Kavanagh; Noreen Morris; John D Power; Geraldine Dowling; Brendan Twamley; John O'Brien; Gary Hessman; Folker Westphal; Donna Walther; Simon D Brandt
Journal:  Drug Test Anal       Date:  2018-05-23       Impact factor: 3.345

2.  Chronic phenmetrazine treatment promotes D2 dopaminergic and α2-adrenergic receptor desensitization and alters phosphorylation of signaling proteins and local cerebral glucose metabolism in the rat brain.

Authors:  Bradley M Keegan; Annie L Dreitzler; Tammy Sexton; Thomas J R Beveridge; Hilary R Smith; Mack D Miller; Bruce E Blough; Linda J Porrino; Steven R Childers; Allyn C Howlett
Journal:  Brain Res       Date:  2021-02-23       Impact factor: 3.610

3.  Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters.

Authors:  Ernesto Solis; Julie A Suyama; Matthew F Lazenka; Louis J DeFelice; S Stevens Negus; Bruce E Blough; Matthew L Banks
Journal:  Sci Rep       Date:  2016-08-12       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.